CY1119192T1 - Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα - Google Patents
Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτηταInfo
- Publication number
- CY1119192T1 CY1119192T1 CY20171100845T CY171100845T CY1119192T1 CY 1119192 T1 CY1119192 T1 CY 1119192T1 CY 20171100845 T CY20171100845 T CY 20171100845T CY 171100845 T CY171100845 T CY 171100845T CY 1119192 T1 CY1119192 T1 CY 1119192T1
- Authority
- CY
- Cyprus
- Prior art keywords
- crystal method
- bio availability
- bio
- availability
- vitro
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30211010P | 2010-02-06 | 2010-02-06 | |
| US31287910P | 2010-03-11 | 2010-03-11 | |
| US31850310P | 2010-03-29 | 2010-03-29 | |
| US33304110P | 2010-05-10 | 2010-05-10 | |
| US33302810P | 2010-05-10 | 2010-05-10 | |
| US35954410P | 2010-06-29 | 2010-06-29 | |
| US12/847,568 US8399023B2 (en) | 2009-07-31 | 2010-07-30 | Crystallization method and bioavailability |
| PCT/US2010/043892 WO2011014766A2 (en) | 2009-07-31 | 2010-07-30 | Crystallization method and bioavailability |
| PCT/US2010/043916 WO2011014781A1 (en) | 2009-07-31 | 2010-07-30 | Novel oral forms of a phosphonic acid derivative |
| US37981410P | 2010-09-03 | 2010-09-03 | |
| US45577810P | 2010-10-26 | 2010-10-26 | |
| PCT/US2011/023427 WO2011097269A1 (en) | 2010-02-06 | 2011-02-02 | Crystallization method and bioavailability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119192T1 true CY1119192T1 (el) | 2018-02-14 |
Family
ID=44355747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100845T CY1119192T1 (el) | 2010-02-06 | 2017-08-07 | Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2531200B1 (enExample) |
| JP (2) | JP5792748B2 (enExample) |
| AU (2) | AU2012216632B2 (enExample) |
| CA (1) | CA2826548A1 (enExample) |
| CY (1) | CY1119192T1 (enExample) |
| DK (1) | DK2531200T3 (enExample) |
| ES (1) | ES2638072T3 (enExample) |
| HR (1) | HRP20171201T1 (enExample) |
| HU (1) | HUE035744T2 (enExample) |
| IL (1) | IL221306A0 (enExample) |
| LT (1) | LT2531200T (enExample) |
| PL (1) | PL2531200T3 (enExample) |
| PT (1) | PT2531200T (enExample) |
| SI (1) | SI2531200T1 (enExample) |
| WO (1) | WO2011097269A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| DK2459176T3 (en) | 2009-07-31 | 2017-12-04 | Gruenenthal Gmbh | Crystallization process and bioavailability |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| EP2458996B1 (en) * | 2009-07-31 | 2016-09-07 | Thar Pharmaceuticals, Inc. | Novel oral forms of a phosphonic acid derivative |
| DK2531200T3 (en) * | 2010-02-06 | 2017-09-11 | Gruenenthal Gmbh | COSTALLIZATION PROCEDURE AND BIOTA ACCESSIBILITY |
| US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
| CN102268023B (zh) * | 2011-08-15 | 2013-04-17 | 南京丰融化学技术有限公司 | 头孢类衍生物cxd的晶型 |
| US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
| US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
| US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| EP3323418A1 (en) * | 2012-05-14 | 2018-05-23 | Antecip Bioventures II LLC | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions |
| US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US20140349974A1 (en) * | 2014-08-12 | 2014-11-27 | Antecip Bioventures Ii Llc | Zoledronic acid dosage forms for the treatment of pain |
| US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US10188617B2 (en) | 2013-03-12 | 2019-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of cellular DNA repair activity to intercept malignancy |
| EP4681719A3 (en) * | 2013-03-15 | 2026-04-15 | XORTX Therapeutics Inc. | Xanthine oxidase inhibitor formulations |
| JP6166471B2 (ja) * | 2013-10-25 | 2017-07-19 | アンテシップ バイオベンチャーズ トゥー エルエルシー | ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 |
| KR20180053384A (ko) * | 2015-09-18 | 2018-05-21 | 그뤼넨탈 게엠베하 | 결정화 방법 및 생체이용률 |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| KR102723076B1 (ko) * | 2016-12-15 | 2024-11-28 | 제이투에이치바이오텍 (주) | 3성분 코크리스탈 |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| JP2022529781A (ja) | 2019-04-17 | 2022-06-24 | コンパス パスファインダー リミテッド | サイロシビンによるうつ病及び他の様々な障害の治療 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
| WO2003007916A1 (en) | 2001-07-17 | 2003-01-30 | Teva Pharmaceutical Industries Ltd. | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| US20040220264A1 (en) * | 2003-03-17 | 2004-11-04 | Yu Ruey J | Bioavailability and improved delivery of acidic pharmaceutical drugs |
| CA2530193A1 (en) * | 2003-07-03 | 2005-01-20 | Teva Pharmaceutical Industries Ltd. | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
| US20060068010A1 (en) | 2004-09-30 | 2006-03-30 | Stephen Turner | Method for improving the bioavailability of orally delivered therapeutics |
| JO3006B1 (ar) * | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| EP2458996B1 (en) * | 2009-07-31 | 2016-09-07 | Thar Pharmaceuticals, Inc. | Novel oral forms of a phosphonic acid derivative |
| DK2459176T3 (en) * | 2009-07-31 | 2017-12-04 | Gruenenthal Gmbh | Crystallization process and bioavailability |
| DK2531200T3 (en) * | 2010-02-06 | 2017-09-11 | Gruenenthal Gmbh | COSTALLIZATION PROCEDURE AND BIOTA ACCESSIBILITY |
| US9340565B2 (en) * | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
| CN102070668B (zh) * | 2010-12-23 | 2013-07-24 | 蚌埠丰原医药科技发展有限公司 | 一种利用相转移催化剂制备唑来膦酸及其钠盐的方法 |
-
2011
- 2011-02-02 DK DK11740284.2T patent/DK2531200T3/en active
- 2011-02-02 ES ES11740284.2T patent/ES2638072T3/es active Active
- 2011-02-02 EP EP11740284.2A patent/EP2531200B1/en not_active Not-in-force
- 2011-02-02 CA CA2826548A patent/CA2826548A1/en not_active Abandoned
- 2011-02-02 LT LTEP11740284.2T patent/LT2531200T/lt unknown
- 2011-02-02 PL PL11740284T patent/PL2531200T3/pl unknown
- 2011-02-02 PT PT117402842T patent/PT2531200T/pt unknown
- 2011-02-02 HU HUE11740284A patent/HUE035744T2/en unknown
- 2011-02-02 WO PCT/US2011/023427 patent/WO2011097269A1/en not_active Ceased
- 2011-02-02 HR HRP20171201TT patent/HRP20171201T1/hr unknown
- 2011-02-02 SI SI201131269T patent/SI2531200T1/sl unknown
- 2011-02-02 JP JP2012552048A patent/JP5792748B2/ja not_active Expired - Fee Related
-
2012
- 2012-08-05 IL IL221306A patent/IL221306A0/en unknown
- 2012-09-04 AU AU2012216632A patent/AU2012216632B2/en not_active Ceased
-
2015
- 2015-08-06 JP JP2015156109A patent/JP6190429B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-25 AU AU2016219653A patent/AU2016219653B2/en not_active Ceased
-
2017
- 2017-08-07 CY CY20171100845T patent/CY1119192T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2531200A4 (en) | 2014-01-08 |
| ES2638072T3 (es) | 2017-10-18 |
| PL2531200T3 (pl) | 2017-10-31 |
| JP2013519632A (ja) | 2013-05-30 |
| HRP20171201T1 (hr) | 2017-10-06 |
| AU2016219653B2 (en) | 2018-05-31 |
| IL221306A0 (en) | 2012-10-31 |
| DK2531200T3 (en) | 2017-09-11 |
| EP2531200A1 (en) | 2012-12-12 |
| SI2531200T1 (sl) | 2017-12-29 |
| WO2011097269A1 (en) | 2011-08-11 |
| AU2016219653A1 (en) | 2016-09-15 |
| WO2011097269A9 (en) | 2012-12-27 |
| JP5792748B2 (ja) | 2015-10-14 |
| JP6190429B2 (ja) | 2017-08-30 |
| AU2012216632B2 (en) | 2016-05-26 |
| PT2531200T (pt) | 2017-08-24 |
| CA2826548A1 (en) | 2011-08-11 |
| LT2531200T (lt) | 2017-09-25 |
| HUE035744T2 (en) | 2018-05-28 |
| EP2531200B1 (en) | 2017-07-12 |
| JP2016006096A (ja) | 2016-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016219653A1 (en) | Crystallization Method and Bioavailability | |
| CY1121952T1 (el) | Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα | |
| CY1121373T1 (el) | Μεθοδος και φαρμακοτεχνικη μορφη για εισπνοη | |
| CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
| PL2588091T3 (pl) | Sposoby dostarczania medycznej substancji czynnej poprzez podawanie wyrobów do higieny osobistej zawierających filament | |
| CO2018003558A2 (es) | Método de cristalización y biodisponibilidad | |
| CY1121472T1 (el) | Συστημα οφθαλμικης αποδεσμευσης φαρμακου που περιεχει φωσφολιπιδιο και χοληστερολη | |
| CY1118661T1 (el) | Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων | |
| CY1118813T1 (el) | Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων | |
| TW201129382A (en) | Antibody formulation and therapeutic regimens | |
| PH12014502778A1 (en) | Antibody formulation | |
| EA033374B1 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| EA201270780A1 (ru) | С-3 модифицированные производные бетулиновой кислоты в качестве ингибиторов созревания вич | |
| MX347504B (es) | Formulaciones concentradas de proteina y usos de las mismas. | |
| MX2012007806A (es) | Composiciones farmaceuticas para administracion oral de peptidos de insulina. | |
| FI20135146A7 (fi) | Farmaseuttiset koostumukset ja hoitomenetelmät | |
| UA107550C2 (uk) | Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів | |
| LT2013018A (lt) | Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus | |
| BR112013030644A2 (pt) | fosfolipídios contendo ácido(s) nitrocarboxílico(s) da estrutura geral (i), e uso dos mesmos, dispositivo médico e composições biopassivadoras | |
| EA201290808A1 (ru) | Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения | |
| PH12015502556A1 (en) | Modified release formulation | |
| ZA201203028B (en) | Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin | |
| GEP20156332B (en) | Pyrazoles as crth2 antagonists | |
| MX2013013691A (es) | Composicion de liberacion sostenida que contiene peptidos como ingredientes activos. | |
| CA2818951A1 (en) | Human lactoferrin derived peptide for use as an antigen masking agent |